Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$97.75M, compared with -$88.01M a year earlier. Trailing-twelve-month EBITDA was -$418.36M.
Context
- EBITDA amounted to 756.3% of revenue in FY2025, down 1226.3 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$323.09M (+20.9%) for the fiscal year ending Dec 2026, a step up from the -156.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$97.75M+9.3% QoQ
- Last fiscal yearDec 2025
- -$408.62M-156.5% YoY
- LTMMar 2026
- -$418.36M-158.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.1% | +12.0% | +23.1 pp |
| 1 year | -156.5% | +20.9% | +177.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (408.62M) USD
- Year-over-year change
- -156.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (408.62M) | -156.5% |
| FY2024 | 2024-12-31 | 723.62M | +309.5% |
| FY2023 | 2023-12-31 | (345.47M) | -54.8% |
| FY2022 | 2022-12-31 | (223.24M) | +33.9% |
| FY2021 | 2021-12-31 | (337.73M) | — |
EBITDA vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's LTM Mar 2026 EBITDA of -$418.36M is the 5th highest of the 7 companies compared; the peer median is -$270.52M.
- Its year-over-year change of -158.4% is the 5th highest of 7, against a peer median of -63.3%.
- EBITDA amounts to 633.4% of revenue for AGIO, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $39.48M | +82.4% | -1.9% | 10.7% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | -$238.08M | -47.2% | — | — |
| LTM Jun 2026 | -$302.96M | -577.6% | — | 32.2% | |
| LTM Mar 2026 | -$418.36M | -158.4% | — | 633.4% | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$776.79M | -4033.6% | — | 125.7% | |
| Peer median (excluding AGIO) | -$270.52M | -63.3% | -1.9% | 32.2% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 14.24M | 26.82M | 36.5M | 54.03M |
| Cost of Revenue | 18.78M | 1.7M | 9.5M | 4.17M | 11.52M |
| Gross Profit | (18.78M) | 12.54M | 17.32M | 32.33M | 42.51M |
| Gross Margin | — | 88.0% | 64.6% | 88.6% | 78.7% |
| Research & Development | 256.97M | 279.91M | 288.9M | 301.29M | 334.36M |
| Selling, General & Admin | 121.45M | 121.67M | 119.9M | 156.78M | 180.28M |
| Operating Expenses | 359.64M | 401.58M | 408.81M | 458.07M | 514.64M |
| Depreciation & Amortization | 18.78M | 8.56M | 6.62M | 5.65M | 5.18M |
| EBITDA | (337.73M) | (223.24M) | (345.47M) | 723.62M | (408.62M) |
| EBITDA Margin | — | -1567.7% | -1287.9% | 1982.6% | -756.3% |
| Operating Income | (378.42M) | (389.05M) | (391.49M) | (425.74M) | (472.13M) |
| Operating Margin | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Interest Income | 836K | 12.79M | 33.34M | 48.08M | 56.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 21.91M | 157.25M | 39.4M | 1.14B | 58.34M |
| Income Before Tax | (356.51M) | (231.8M) | (352.09M) | 717.97M | (413.8M) |
| Pre-Tax Margin | — | -1627.8% | -1312.6% | 1967.1% | -765.9% |
| Income Tax Expense | 0 | 0 | 0 | 44.24M | (1.02M) |
| Net Income | 1.6B | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Net Margin | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (Basic) | (6.36) | (4.23) | (6.33) | 11.86 | (7.12) |
| EPS (Diluted) | (6.36) | (4.23) | (6.33) | 11.64 | (7.12) |
| Weighted Avg Shares | 60.45M | 54.79M | 55.65M | 56.81M | 57.97M |
| Weighted Avg Shares (Diluted) | 60.45M | 54.79M | 55.65M | 57.89M | 57.97M |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.